R R

What Are Carbonic Anhydrase Inhibitors?

Carbonic Anhydrase Inhibitors (CAIs) are a class of diuretic medications that function by blocking the activity of the enzyme carbonic anhydrase, which is present in various parts of the body, including the eye, kidneys, and central nervous system. This pharmacological action forms the basis for their diverse clinical applications, which range from treating neurological disorders to managing high intraocular pressure. In ophthalmology, CAIs are a standard component of drug therapy for glaucoma, a disease characterized by progressive optic nerve damage linked to elevated eye pressure.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Are Carbonic Anhydrase Inhibitors?

Carbonic Anhydrase Inhibitors (CAIs) are a class of diuretic medications that function by blocking the activity of the enzyme carbonic anhydrase, which is present in various parts of the body, including the eye, kidneys, and central nervous system. This pharmacological action forms the basis for their diverse clinical applications, which range from treating neurological disorders to managing high intraocular pressure. In ophthalmology, CAIs are a standard component of drug therapy for glaucoma, a disease characterized by progressive optic nerve damage linked to elevated eye pressure.

read more about carbonic anhydrase inhibitors ...

Copy this HTML:

Copy HTML Copied!

How Do Carbonic Anhydrase Inhibitors Work?

In the eye, Carbonic Anhydrase Inhibitors lower Intraocular Pressure (IOP) by suppressing the secretion of aqueous humor, the fluid that fills the front of the eye. The carbonic anhydrase enzyme is needed for the production of aqueous humor within the ciliary body of the eye. By inhibiting this enzyme, CAIs reduce the rate at which fluid is produced, which subsequently decreases the fluid volume and pressure inside the eye, addressing the most treatable risk factor for glaucoma.

Glaucoma is managed by maintaining a lowered IOP, and CAIs are a versatile tool in this strategy. They are used as monotherapy (the sole treatment) or as adjunctive therapy in combination with other anti-glaucoma drops, such as prostaglandin analogs or beta-blockers. The drugs are available in two forms: systemic (oral tablets) like acetazolamide, methazolamide, and dichlorophenamide, or local (topical eye drops) like dorzolamide and brinzolamide.

What Are Carbonic Anhydrase Inhibitors Used For?

CAIs have a wide range of FDA-approved applications, reflecting the enzyme's role in multiple physiological processes throughout the body. Their primary ophthalmic indication is the management of elevated intraocular pressure associated with open-angle and angle-closure glaucoma.

Beyond eye disease, CAIs are indicated for treating other conditions, primarily due to their diuretic properties that affect fluid balance and acidity. These uses include managing edema (fluid retention) due to congestive heart failure, treating pseudotumor cerebri (idiopathic intracranial hypertension), and managing certain types of epilepsy. They are also prescribed as a prophylactic measure for altitude sickness to help the body acclimatize faster to high elevations.

What Is The Difference Between Systemic And Topical Carbonic Anhydrase Inhibitors?

CAIs are categorized into two generations based on their formulation and route of administration. First-generation inhibitors, such as acetazolamide, are administered systemically as oral drugs for glaucoma management, but these are associated with severe, systemic adverse effects, including acid-base and electrolyte disturbances.

The second generation includes dorzolamide and brinzolamide, which are formulated as topical eye drops. These topical forms have significantly fewer and less severe systemic side effects compared to oral drugs because they are applied directly to the eye, reducing systemic absorption. Topical CAIs are the preferred modern treatment option when systemic side effects are a concern or when patients have contraindications for other common anti-glaucoma drugs, such as beta-blockers.

When Are Carbonic Anhydrase Inhibitors Prescribed For Glaucoma?

CAIs are introduced as part of a multi-drug regimen when a patient's Intraocular Pressure (IOP) is not adequately controlled by first-line agents, such as prostaglandin analogs, or when those agents are contraindicated. For instance, they are beneficial for patients with asthma, reactive airways disease, or heart conditions who are unable to use beta-adrenergic antagonists.

They are also used for short-term, acute pressure reduction. In cases of acute angle-closure glaucoma, systemic CAIs may be given initially to rapidly lower dangerously high pressure before definitive surgical or laser treatment can be administered. Topical CAIs are favored for long-term use due to their reduced systemic side-effect profile, making them a safe and effective component of ongoing maintenance therapy.

Frequently Asked Questions

What Are The Side Effects Of Carbonic Anhydrase Inhibitors?

The side effect profile differs significantly between oral and topical CAIs. Systemic (oral) CAIs are linked to severe adverse effects, including electrolyte imbalances, angle-closure glaucoma, bilateral transient myopia, and changes in color vision.

Topical CAIs are generally well-tolerated, with most side effects being local and transient. The most common local effects include transient burning, stinging, or discomfort upon application. The most frequently reported systemic side effect of topical CAIs is a bitter or metallic taste, known as dysgeusia, which is reported in approximately 25 percent of patients. This taste occurs when the drug-laden tear film drains into the throat, inhibiting the carbonic anhydrase enzyme in saliva.

How Quickly Do Topical Cais Begin To Lower Eye Pressure?

Topical CAIs demonstrate a rapid onset of action. For example, dorzolamide is effective in lowering Intraocular Pressure (IOP) with peak reduction achieved approximately two hours post-dose.

Can A Patient With A Sulfa Allergy Use Topical Cais?

Although CAIs are sulfonamide inhibitors, clinical studies have not demonstrated that topical CAIs induce more allergic reactions in patients with a sulfa allergy compared to those without. However, providers may still avoid oral CAIs in patients with a history of severe hypersensitivity.

What Is The Main Cosmetic Side Effect Associated With Topical Cais?

The most common and bothersome systemic side effect is a transient bitter or metallic taste, which is caused by the medicated tears draining through the tear ducts into the back of the throat.

References

NIH National Library of Medicine (NCBI). Carbonic Anhydrase Inhibitors. https://www.ncbi.nlm.nih.gov/books/NBK557736/

PubMed. Carbonic Anhydrase Inhibitors in the Treatment of Glaucoma. https://pubmed.ncbi.nlm.nih.gov/24146387/

MDPI. Ocular Side Effects of Glaucoma Medications. https://www.mdpi.com/2813-1053/3/1/2

PMC. Attitude toward CAI Prescription in Patients with History of Sulfonamide Antibiotic Hypersensitivity. https://pmc.ncbi.nlm.nih.gov/articles/PMC12089305/

MDPI. Pharmacotherapy of Glaucoma. https://www.mdpi.com/2673-9879/4/2/22

PubMed. Dorzolamide: A Review of its Pharmacology, Clinical Efficacy and Tolerability in the Management of Glaucoma. https://pubmed.ncbi.nlm.nih.gov/9143858/

PubMed. Brinzolamide: A Review of its Use in the Management of Glaucoma and Ocular Hypertension. https://pubmed.ncbi.nlm.nih.gov/14565787/

Mayo Clinic. Dorzolamide (Ophthalmic Route) Description. https://www.mayoclinic.org/drugs-supplements/dorzolamide-ophthalmic-route/description/drg-20063524

American Academy of Ophthalmology (AAO). Angle-Closure Glaucoma. https://www.aao.org/current-insight/angleclosure-glaucoma-19

References